资讯

Second patient death reported with gene therapy for muscular dystrophy
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...
Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella ...
Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...
BioWorld1 天
Cure Rare Disease completes pre-IND meeting for limb girdle muscular dystrophy gene therapy ...
Cure Rare Disease has successfully completed a pre-IND meeting with the FDA regarding its investigational gene therapy program for limb-girdle muscular dystrophy type 2I/R9 (LGMDR9).
2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy
Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene ...
The Baltimore Sun9 天
Second death reported with gene therapy for muscular dystrophy - Baltimore Sun
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported ...
Press Enterprise Online4 天
Gene therapy for muscular dystrophy sees a second death
Shares of Sarepta Therapeutics plunged after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.
The Hamilton Spectator10 天
Second patient death reported with gene therapy for muscular dystrophy
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.
Yahoo Finance10 天
Second patient death reported with gene therapy for muscular dystrophy - Yahoo Finance
Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the death over the ...
MedCity News10 天
Sarepta Stops Stop Shipments of Muscular Dystrophy Gene Therapy After Second Patient Death
A patient has died after receiving Sarepta Therapeutics’ approved gene therapy for Duchenne muscular dystrophy — the second fatality reported by the company in the past three months. Like the ...